Exenatide once weekly for the treatment of type 2 diabetes mellitus: Clinical results in subgroups of patients using different concomitant medications

Postgraduate Medicine

Volumn 124, Issue 4, 2012, Pages 33-40

  Pencek, Richard ^a   Brunell, Steven C ^a   Li, Yan ^a   Hoogwerf, Byron J ^b   Malone, James ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Concomitant treatment; Diabetes; Exenatide once weekly; GLP 1

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ADULT; ARTICLE; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE NODULE; INJECTION SITE PRURITUS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; INTENTION TO TREAT ANALYSIS; MIDDLE AGED;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INTENTION TO TREAT ANALYSIS; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 84871697848     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2568     Document Type: Article

References (27)

1. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3):153-165.
2. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
3. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199-E206.
4. Orskov C, Holst JJ, Nielsen OV Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123(4):2009-2013.
5. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239-1246.
6. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 pt 1):E981-E988.
7. Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271(4 pt 2):R848-R856.
8. Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab. 2011;96(6):1763-1770.
9. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294(5):E846-E852.
10. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082-3089.
11. Tracy MA, Ward KL, Firouzabadian L, et al. Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999;20(11):1057-1062.
12. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145-1154.
13. Handelsman Y, Mechanick JI, Blonde L, et al; AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17(2):287-302.
14. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
15. Drucker D, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
16. Bergenstal RM, Wysham C, MacConell L, et al; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-439.
17. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.
18. Russell-Jones D, Cuddihy RM, Hanefeld M, et al; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week, double-blind study. Diabetes Care. 2012;35(2):252-258.
19. Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310.
20. Buse B, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study [abstract 75]. Diabetologia. 2011;54(suppl 1):S38.
21. Ji LN, Onishi Y, Woo AC, et al. Efficacy and safety of exenatide once weekly versus exenatide twice daily in patients of Pan-Asian descent with type 2 diabetes. World Diabetes Congress Abstract Book. 2011; P1144.
22. BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2012.
23. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303.
24. Matthews DR Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167-174.
25. Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther. 2010;12(6):491-501.
26. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
27. Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract. 2012;18(2):227-237.